STOCK TITAN

Cytek Biosciences director gets 4,629 shares at vesting

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Cytek Biosciences, Inc. director Glenn P. Muir reported that 4,629 restricted stock units converted into 4,629 common shares on November 18, 2026. His direct common-stock holdings afterward were 7,715 shares; the reported post-transaction restricted-stock-unit balance was 47,840 units. The award’s shares vest over three years under the schedule described in the footnote.

Insider MUIR GLENN P
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Units F1, F2 4,629 $0.00 $0.00
Exercise Common Stock F1 4,629 -- --
Holdings After Transaction: Restricted Stock Units — 47,840 units (Direct); Common Stock — 7,715 shares (Direct)
Holdings Before and After: Restricted Stock Units, 52,469 to 47,840 units (Direct); Common Stock, 3,086 to 7,715 shares (Direct)
Footnotes (2)
  1. F1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
  2. F2. The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter.
Restricted stock units converted 4,629 units November 18, 2026
Common shares acquired 4,629 shares November 18, 2026
Direct common shares after transaction 7,715 shares Reported following the November 18, 2026 transaction
Restricted stock units after transaction 47,840 units Reported following the November 18, 2026 transaction
RSU Award technical
"Each Restricted Stock Unit (the "RSU Award")"
contingent right technical
"represents a contingent right to receive one share"
vest technical
"shares underlying the RSU Award shall vest over 3 years"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CTKB shares did director Glenn P. Muir acquire from RSUs?

Glenn P. Muir acquired 4,629 common shares through the vesting and conversion of 4,629 restricted stock units on November 18, 2026. His direct common-stock holdings afterward were 7,715 shares; no Rule 10b5-1 plan is reported.

What is the CTKB RSU vesting schedule?

The award vests over 3 years: 2/36 vested on August 18, 2026; 3/36 on November 18, 2026 and each November 18 thereafter; 4/36 on March 10, 2027 and each March 10 thereafter; 3/36 on May 18, 2027 and each May 18 thereafter; and 3/36 on August 18, 2027 and each August 18 thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MUIR GLENN P

(Last)(First)(Middle)
C/O CYTEK BIOSCIENCES, INC.
47215 LAKEVIEW BOULEVARD

(Street)
FREMONT CALIFORNIA 94538

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/18/2026M4,629A(1)7,715D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)11/18/2026M4,629 (2) (2)Common Stock4,629$047,840D
Explanation of Responses:
1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
2. The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter.
/s/ Wenbin Jiang, Attorney-in-Fact11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading